

CVD escalation therapy for secondary prevention (update) committee meeting 4

Date: 11/5/2023

Location: Wandle 41+40, NICE offices, 2 Redman Place, London E20 1JQ
and via Zoom

Minutes: Final

Committee members present:	
Nigel Beckett	Present for items 1-6
Chris Clark	
Hugh Gallagher	
Satwinder Kaur	
Paul Leeson	
Joseph Mills (Chair)	
Riyaz Patel (Topic adviser)	
David Preiss	
Ruth Price	
Chakravarthi Rajkumar (Co-opted member)	Present for items 1-4
Eduard Shantsila	
Wayne Sunman	
Colin Wilkinson	

In attendance:		
Elaine Cartwright	Associate Director, Resource Impact Assessment	
Serena Carville	Associate Director/Guideline Lead	
Catrina Charlton	Guideline Commissioning Manager	
Kusal Lokuge	Technical Analyst (Economics)	
Alfredo Mariani	Technical Analyst (Economics)	
Edgar Masanga	Resource Impact Lead	
Joanna Perkin	Medical Editor	

4.0.03 DOC Cmte minutes

Eric Power	Programme Director, Centre for Guidelines	
Eleanor Samarasekera	Senior Systematic Reviewer	
Sharon Swain	Associate Director, GDT NGC	
Amelia Unsworth	Senior Project Manager	
Melina Vasileiou	Technical Analyst	
David Wonderling	Head of Health Economics	
Miaoqing Yang	Technical Analyst (Economics)	

NICE observers:

Charlotte Fairclough	Technical Adviser, Quality standards & indicators team
----------------------	---

Apologies:

Beverley Bostock	Committee member
Parijat De	Co-opted member
Aroon Hingorani	Co-opted member
Lina Gulhane	Head of Information Specialists, GDT NGC

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 4th meeting on CVD escalation therapy for secondary prevention.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: discussion of the updated results of the economic model and discussion of the draft recommendations.

2. Confirmation of matters under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

- lipid-lowering therapies for escalation of therapy for secondary prevention for

4.0.03 DOC Cmte minutes

people with CVD.

The Chair asked everyone to verbally declare any interests in addition to those previously declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Chris Clark	Clinical Senior Lecturer in Primary Care, University of Exeter Medical School	Contributed to the Canadian Task Force on Preventative Healthcare guideline update process and a named author on the protocol for searching for the evidence to update the guideline. The manuscript is currently in submission. This concludes my involvement, 11.5.23.	Direct non-financial professional and personal	Non-specific No action needed other than process of open declaration
Ruth Price	Advanced Clinical Pharmacist for Cardiovascular Services, Leeds Teaching Hospitals NHS Trust	Lead author for a paper “Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedback” published in BMJ Open Quality in April 2023, 11.5.23.	Direct non-financial professional and personal	Non-specific No action needed other than process of open declaration
Joseph Mills	Consultant Cardiologist, Liverpool Heart & Chest Hospital	Co-presented a GP educational webinar “Cardiovascular disease masterclass”, organised by “Issues & Answers in Primary Care” (the educational arm of the primary care cardiovascular journal). Received an honorarium for his time preparing the case study and giving the presentation, 11.5.23.	Direct financial	Non-specific No statements were made on areas to be covered in this update. No action needed other than process of open declaration.

CCI declared that he has been contributing to the Canadian Task Force on

4.0.03 DOC Cmte minutes

Preventative Healthcare guideline update process and that he is a named author on the protocol for searching for the evidence to update the guideline. The manuscript is currently in submission. This concludes CCI's involvement. The Chair and a senior member of the developer team did not consider that this interest posed a conflict with the topic under consideration and therefore no action was required.

RPr declared that she is the lead author for a paper "Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedback" published in BMJ Open Quality in April 2023. The Chair and a senior member of the Developer's team did not consider that these activities posed a conflict with the matters under discussion, therefore no further action was required.

The Chair declared that he co-presented a GP educational webinar "Cardiovascular disease masterclass", organised by "Issues & Answers in Primary Care" (the educational arm of the primary care cardiovascular journal). JM received an honorarium for his time preparing the case study and giving the presentation. A senior member of the developer team did not consider that this interest posed a conflict with the topic under consideration and therefore no action was required.

The Chair and a senior member of the Developer's team reviewed the declarations of interest register for interests previously declared and noted that none posed a conflict with the matters under discussion, therefore no further action was required.

3. Aims and remit

The Committee was given a presentation on a reminder of the remit and scope of the update, and the aims of the meeting.

4. Health economic model: data and inputs update

The Committee was given a presentation on the health economic model's updated data and inputs.

5. Health economic model: updated results

The Committee was given a presentation on the updated results of the health economic model.

6. Recommendations

The Committee discussed the draft recommendations.

7. Minutes of the previous meeting

The minutes of the previous meeting were agreed as an accurate record.

4.0.03 DOC Cmte minutes

8. Timeline and next steps
The Committee was given an update on the timeline and next steps.
9. Any other business
None

Date of next meeting: 31/7/23

Location of next meeting: Virtual via Zoom